NRX Pharmaceuticals, Inc. 8-K

What Happened

• On February 17, 2026, NRX Pharmaceuticals, Inc. (NRXP) filed a Form 8‑K and issued a press release reporting that, following a Type C meeting with the FDA, the company has a defined path toward submitting a new drug application (NDA) for NRX‑100 (ketamine). The company said this path would incorporate real‑world data and supports a broader proposed indication for NRX‑100. The press release is attached to the 8‑K as Exhibit 99.1.

Key Details

• Filing date: February 17, 2026 (Form 8‑K).
• Product: NRX‑100 (ketamine).
• Regulatory milestone: Outcome of a Type C FDA meeting outlining a path to an NDA.
• Evidence approach: Company intends to use real‑world data and pursue a broader proposed indication for NRX‑100.

Why It Matters

• This filing signals regulatory progress: a Type C meeting outcome that identifies an NDA pathway is a material step in development toward potential approval.
• Use of real‑world data and a broader proposed indication could affect the scope of the evidence package and the potential commercial market if approval is achieved.
• For investors, this is a development to watch for follow‑up details from the company or FDA about specific data requirements, timelines, and any formal submissions; the 8‑K itself reports the meeting outcome but does not provide specific submission dates or commitments.